The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia

This study is testing whether a bone marrow transplant from a donor (allogeneic hematopoietic stem cell transplantation) can improve outcomes for people newly diagnosed with a specific type of leukemia called CEBPA-mutant AML, particularly those with features that predict a higher chance of relapse. **You may be eligible if...** - You have been newly diagnosed with AML and your leukemia has a mutation in the CEBPA gene, confirmed by genetic testing - Your disease has high-risk features such as additional gene mutations (e.g., CD7 positive, WT1 mutation), complex chromosomal changes, or measurable residual disease after two rounds of chemotherapy **You may NOT be eligible if...** - Your leukemia does not have a CEBPA mutation - Your disease does not meet the high-risk criteria - You have achieved a deep molecular remission without residual disease Talk to your doctor to see if this trial is right for you.